Rani Therapeutics Holdings Inc
NASDAQ:RANI

Watchlist Manager
Rani Therapeutics Holdings Inc Logo
Rani Therapeutics Holdings Inc
NASDAQ:RANI
Watchlist
Price: 1.305 USD -2.61%
Market Cap: $158.6m

Net Margin

-2 359.6%
Current
Improving
by 199.6%
vs 3-y average of -2 559.2%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-2 359.6%
=
Net Income
$-28.3m
/
Revenue
$1.2m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-2 359.6%
=
Net Income
$-28.3m
/
Revenue
$1.2m

Peer Comparison

Country Company Market Cap Net
Margin
US
Rani Therapeutics Holdings Inc
NASDAQ:RANI
160.4m USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
969.6B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
547.3B USD
Loading...
CH
Roche Holding AG
SIX:ROG
277.1B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
209.4B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
271.3B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
148.3B USD
Loading...
FR
Sanofi SA
PAR:SAN
93.8B EUR
Loading...

Market Distribution

Lower than 95% of companies in the United States of America
Percentile
5th
Based on 15 072 companies
5th percentile
-2 359.6%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Rani Therapeutics Holdings Inc
Glance View

Market Cap
158.6m USD
Industry
Pharmaceuticals

Rani Therapeutics Holdings, Inc. operates as a clinical stage bio-therapeutics company providing technologies to enable the development of orally administered biologics. The company is headquartered in San Jose, California and currently employs 114 full-time employees. The company went IPO on 2021-07-30. The Company’s technologies enable the development of orally administered biologics. The firm has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which delivers any drug, including molecules, such as peptides, proteins and antibodies. The RaniPill capsule delivers up to a three micrograms (mg) dose of the drug with high bioavailability. Its capsule includes a coating that is designed to withstand stomach acid but dissolves in the jejunum portion of the small intestine. The Company’s product candidate RaniPill capsule is in Phase I clinical trial. The Company’s RaniPill capsule is delivering a variety of biological therapeutics. Its pipeline includes core product candidate programs, such as RT-101, RT-105, RT-102, RT-109 and RT-110. The firm manufactures and assembles RaniPill capsules at its facilities in San Jose and Milpitas, California.

RANI Intrinsic Value
0.384 USD
Overvaluation 71%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-2 359.6%
=
Net Income
$-28.3m
/
Revenue
$1.2m
What is Rani Therapeutics Holdings Inc's current Net Margin?

The current Net Margin for Rani Therapeutics Holdings Inc is -2 359.6%, which is above its 3-year median of -2 559.2%.

How has Net Margin changed over time?

Over the last 8 months, Rani Therapeutics Holdings Inc’s Net Margin has increased from -2 920% to -2 359.6%. During this period, it reached a low of -2 920% on Dec 31, 2024 and a high of -2 359.6% on Sep 30, 2025.

Back to Top